JC Ansquer, C Foucher, P Aubonnet, K Le … - Current pharmaceutical design, 2009 - ingentaconnect.com Abstract: Fibrates are widely prescribed lipid-lowering drug in the treatment of
dyslipidemia. Their main clinical effects, mediated by peroxisome proliferative
activated receptor (PPAR) alpha activation, are a moderate reduction in ... Cited by 7 - Related articles - All 3 versions
JC Ansquer, I Bekaert, M Guy, M Hanefeld, A … - American Journal Cardiovascular Drugs: Volume, 2009 - pt.wkhealth.com Background: Patients with type IIb, or mixed, dyslipidemia have high levels of
low-density lipoprotein cholesterol (LDL-C) with predominance of small dense LDL
particles, high levels of triglycerides (TG), and low levels of ...
JC Ansquer, I Bekaert, M Guy, M Hanefeld, A … - American Journal of Cardiovascular Drugs, 2009 - ingentaconnect.com Page 1. Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe
Compared with Each as Monotherapy in Patients with Type ... Related articles - All 5 versions